Where do the answers lie to aging?
Conboy said that after demonstrating efficacy in the pilot study, plans are under way for a Phase 3 placebo-controlled trial involving 200-300 people to demonstrate the use of plasma dilution technology as a treatment that is innovative for co-morbidities associated with aging.
This could be the very first bridge.
Irina conboy, UC Berkeley, talks about parabiosis and plasma dilution. She also explains why young blood might not be the answer to all questions.
Source:
